Completed
A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis
What is being tested
Alcaftadine 0.25%
+ Olopatadine 0.2%
+ dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
Drug
Who is being recruted
Conjunctival Diseases+4
+ Conjunctivitis
+ Conjunctivitis, Allergic
Over 10 Years
+5 Eligibility Criteria
How is the trial designed
Treatment Study
Placebo-ControlledPhase 4
Interventional
Study Start: November 2012
Summary
Principal SponsorAllergan
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner
Study start date: November 1, 2012
Actual date on which the first participant was enrolled.This study will evaluate the efficacy of Lastacaft® (Alcaftadine 0.25%) and Pataday™ (Olopatadine 0.2%) as compared to each other and to placebo in the prevention of ocular itching associated with allergic conjunctivitis.
Official TitleA Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis
Principal SponsorAllergan
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
157 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.Over 10 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Conjunctival DiseasesConjunctivitisConjunctivitis, AllergicEye DiseasesHypersensitivityHypersensitivity, ImmediateImmune System Diseases
Criteria
2 inclusion criteria required to participate
History of ocular allergies within the past 24 months.
Able to avoid wearing contact lenses for at least 72 hours prior to and during the study trial period.
3 exclusion criteria prevent from participating
Any presence of active ocular infection or history of an ocular herpetic infection.
Ocular surgery within 3 months prior to the first visit or refractive surgery within the past 6 months.
Have any planned surgery during the study or 30 days after the study.
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Treatment Groups
Study Objectives
3 intervention groups are designated in this study
33.333% chance of being blinded to the placebo group
Treatment Groups
Group I
Active ComparatorOne drop of Lastacaft® (Alcaftadine 0.25%) administered in both eyes on Day 0.
Group II
Active ComparatorOne drop of Pataday™ (Olopatadine 0.2%) administered in both eyes on Day 0.
Group III
PlaceboOne drop of Placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%) administered in both eyes on Day 0.
Study Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has no location dataSave this study to your profile to know when the location data is available.
CompletedNo study centers